Results 1 to 10 of about 17,215 (292)

Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Artemisinin‐based combination therapy (ACT) is the first‐line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant ...
Junjie Ding, Richard M. Hoglund, Harry Tagbor, Halidou Tinto, Innocent Valéa, Victor Mwapasa, Linda Kalilani‐Phiri, Jean‐Pierre Van Geertruyden, Michael Nambozi, Modest Mulenga, Sebastian Hachizovu, Raffaella Ravinetto, Umberto D'Alessandro, Joel Tarning   +13 more
doaj   +3 more sources

Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria

Malaria Journal, 2021
Background Accurate measurement of anti-malarial drug concentrations in therapeutic efficacy studies is essential to distinguish between inadequate drug exposure and anti-malarial drug resistance, and to inform optimal anti-malarial dosing in key target ...
Thomas A. Anyorigiya, Sandra Castel, Katya Mauff, Frank Atuguba, Bernhards Ogutu, Abraham Oduro, David Dosoo, Kwaku-Poku Asante, Seth Owusu-Agyei, Alexander Dodoo, Abraham Hodgson, Fred Binka, Lesley J. Workman, Elizabeth N. Allen, Paolo Denti, Lubbe Wiesner, Karen I. Barnes   +16 more
doaj   +2 more sources

The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis.

PLoS Medicine, 2021
BackgroundAmodiaquine is a 4-aminoquinoline antimalarial similar to chloroquine that is used extensively for the treatment and prevention of malaria.
Xin Hui S Chan, Ilsa L Haeusler, Yan Naung Win, James Pike, Borimas Hanboonkunupakarn, Maryam Hanafiah, Sue J Lee, Abdoulaye Djimdé, Caterina I Fanello, Jean-René Kiechel, Marcus Vg Lacerda, Bernhards Ogutu, Marie A Onyamboko, André M Siqueira, Elizabeth A Ashley, Walter Rj Taylor, Nicholas J White   +16 more
doaj   +2 more sources

Effects of pyrimethamine-sulphadoxine, chloroquine plus chlorpheniramine, and amodiaquine plus pyrimethamine-sulphadoxine on gametocytes during and after treatment of acute, uncomplicated malaria in children [PDF]

Memorias do Instituto Oswaldo Cruz, 2006
The effects of pyrimethamine-sulphadoxine (PS), chloroquine plus chlorpheniramine, a H1 receptor antagonist that reverses chloroquine resistance in Plasmodium falciparum in vitro and in vivo (CQCP), and amodiaquine plus pyrimethamine-sulphadoxine (AQPS ...
A Sowunmi, AA Adedeji, GO Gbotosho, BA Fateye, TC Happi   +4 more
doaj   +2 more sources

Amodiaquine for treating malaria

Cochrane Database of Systematic Reviews, 2003
Amodiaquine has been widely used to treat malaria. Fatal adverse reactions have been reported in adults taking it for prophylaxis. This has led some authorities to suggest it is withdrawn as a first line treatment for malaria.To compare amodiaquine with chloroquine or sulfadoxine-pyrimethamine for treating uncomplicated Plasmodium falciparum malaria.We
Piero Olliaro, Paola Mussano
openalex   +6 more sources

Amodiaquine and Ciprofloxacin Combination in Plasmodiasis Therapy [PDF]

Journal of Tropical Medicine, 2015
Objective. The study was designed to determine the efficacy of combined Amodiaquine and Ciprofloxacin in plasmodiasis therapy. Method. The in vivo antiplasmodial effect of different dosage levels of Amodiaquine, Ciprofloxacin, and their combinations ...
Peace Mayen Edwin Ubulom, Chinweizu Ejikeme Udobi, Mark Iheukwumere Madu   +2 more
doaj   +3 more sources

Dose-Optimization of a Novel Co-Formulated Triple Combination Antimalarial Therapy: Artemether-Lumefantrine-Amodiaquine. [PDF]

Clin Pharmacol Ther
Artemisinin‐based combination therapy (ACT) is the first‐line therapy for uncomplicated falciparum malaria, but artemisinin resistance in Asia and now sub‐Saharan Africa is threatening our ability to control and eliminate malaria. Triple‐ACTs have emerged as a viable alternative treatment to combat declining ACT efficacy due to drug‐resistant malaria ...
Tarning J, White NJ, Dondorp AM.
europepmc   +2 more sources

Low-Cost and Portable Biosensor Based on Monitoring Impedance Changes in Aptamer-Functionalized Nanoporous Anodized Aluminum Oxide Membrane [PDF]

Micromachines
We report a low-cost, portable biosensor composed of an aptamer-functionalized nanoporous anodic aluminum oxide (NAAO) membrane and a commercial microcontroller chip-based impedance reader suitable for electrochemical impedance spectroscopy (EIS)-based ...
Nianyu Jiang, Pranav Shrotriya
doaj   +2 more sources

The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity [PDF]

Cell Death and Differentiation, 2020
Pharmacological inhibition of ribosome biogenesis is a promising avenue for cancer therapy. Herein, we report a novel activity of the FDA-approved antimalarial drug amodiaquine which inhibits rRNA transcription, a rate-limiting step for ribosome ...
Bartek, J., Carreras-Puigvert, J., Espinoza, J.A., Helleday, T., Henriksson, M., Hühn, D., Kanellis, D.C., Lindström, M.S., Watanabe, K., Zisi, A.   +9 more
core   +2 more sources

Artemether-lumefantrine with or without single-dose primaquine and sulfadoxine-pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce Plasmodium falciparum transmission: a phase 2, single-blind, randomised clinical trial in Ouelessebougou, Mali.

Lancet Microbe
Background: Artemether-lumefantrine is widely used for uncomplicated Plasmodium falciparum malaria; sulfadoxine-pyrimethamine plus amodiaquine is used for seasonal malaria chemoprevention.
Mahamar A, Smit MJ, Sanogo K, Sinaba Y, Niambele SM, Sacko A, Dicko OM, Diallo M, Maguiraga SO, Sankaré Y, Keita S, Samake S, Dembele A, Lanke K, Ter Heine R, Bradley J, Dicko Y, Traore SF, Drakeley C, Dicko A, Bousema T, Stone W.   +21 more
europepmc   +2 more sources